Group 1 - The core point of the article is that Shanxi Installation Group Co., Ltd. has received approval from the China Securities Regulatory Commission to issue corporate bonds totaling up to RMB 1.35 billion, marking its first bond issuance since going public [1] - The funds raised from the bond issuance will be used for repaying interest-bearing debts, supplementing operating funds, and project investments [1] - Shanxi Installation is a key state-owned enterprise in Shanxi Province, with total assets of RMB 243.164 billion, and has established a significant position in the engineering services industry, ranking first among professional industrial engineering contractors in Shanxi and fifth nationwide [1] Group 2 - The company was listed on the Hong Kong Stock Exchange on November 22, 2023, becoming the first IPO in the Shanxi construction industry and the second listed company under Shanxi Construction Investment [3] - During its initial public offering, Shanxi Installation issued 330 million shares, raising approximately HKD 727 million, primarily for investment in renewable energy projects and related industry chain layouts [3] - On December 15, 2023, the company announced a further issuance of 40.152 million H-shares, raising about HKD 84.5 million, bringing the total share capital to approximately 1.373 billion shares [3] Group 3 - The share structure includes 1 billion domestic non-listed shares, accounting for 75% of the total, and 333.334 million H-shares, accounting for 25% [5] - Shanxi Construction Investment holds 72.81% of the non-circulating domestic shares, resulting in a "semi-circulating" share structure for Shanxi Installation [5] - The company submitted an application for the overseas listing of its domestic unlisted shares to the China Securities Regulatory Commission, aiming to become the first company in Shanxi to implement full circulation of H-shares [5] Group 4 - Upon completion of the conversion, the circulating shares will increase from 373 million to 1.373 billion, with the total market value expanding from HKD 790 million to HKD 2.91076 billion, based on a share price of HKD 2.120 [6] - The bond issuance is expected to enhance the company's image and reputation in the capital market, boosting investor confidence and establishing a foundation for future fundraising through capital market channels [6]

Core Viewpoint - The Hong Kong biotech sector is experiencing a valuation recovery, with Baojie Pharmaceutical-B (02659) recently listed and announcing a plan for H-share full circulation, converting approximately 63.12 million unlisted shares into tradable H-shares, representing 19.36% of the total share capital [1][2]. Group 1: H-share Full Circulation - The H-share full circulation plan addresses the trading qualification of shares rather than the timing of their trading, enhancing the financial attributes and pricing efficiency of previously static domestic shares [2]. - This move allows Baojie Pharmaceutical to improve liquidity and valuation, enabling major shareholders to engage in financing, equity swaps, or mergers and acquisitions [2]. - The existence of a lock-up period acts as a buffer against immediate stock price impacts, ensuring a stable market environment for the increased liquidity [2]. Group 2: Commercialization Considerations - The implementation of full circulation aims to align shareholder interests with the company's long-term performance, supporting its unique "scenario-driven" strategy [3]. - Baojie Pharmaceutical has developed a "pyramid" pipeline, and the full circulation is expected to attract long-term institutional investors who understand the underlying logic of biopharmaceuticals [3]. - The core product KJ017, a hyaluronidase, is the first of its kind in China to enter the NDA stage, representing a strategic platform that can enable significant advancements in drug delivery [4]. Group 3: Strategic Implications - The full circulation plan links the wealth incentives of the domestic entrepreneurial team to the market performance of rare assets, enhancing their strategic focus on overcoming challenges in the industrialization of protein drugs [5]. - This initiative positions Baojie Pharmaceutical to evolve from a technology-focused biotech company to a biopharma with mature operational capabilities, supported by liquidity premiums that stabilize stock performance [5]. - The company aims to demonstrate that true value creation stems from optimizing capital structure and enhancing the efficiency of medical resource allocation, rather than short-term profit-taking [5].

Core Viewpoint - The Hong Kong biotech sector is experiencing a valuation recovery, with Baoyi Pharmaceutical-B (02659) recently listed and announcing a plan for H-share full circulation, converting approximately 63.12 million unlisted shares into tradable H-shares, representing 19.36% of the total share capital [1][2] Group 1: H-share Full Circulation - The H-share full circulation plan addresses the trading qualification of shares rather than the timing of their trading, enhancing the financial attributes and pricing efficiency of previously static domestic shares [2] - This move allows Baoyi Pharmaceutical to improve liquidity, enabling major shareholders to engage in financing, equity swaps, or mergers and acquisitions, while the existing lock-up period mitigates immediate stock price impacts [2][3] Group 2: Commercialization Considerations - The implementation of full circulation aims to align shareholder interests with the company's long-term performance, supporting its unique "scenario-driven" strategy [3] - Baoyi Pharmaceutical's pipeline, including products like SJ02, KJ017, and KJ103, benefits from increased shareholder structure optimization and the introduction of international capital that understands the underlying logic of biopharmaceuticals [3][4] Group 3: Operational Impact - The full circulation plan provides institutional backing for the commercialization of Baoyi Pharmaceutical's core pipeline, particularly KJ017, which is the first and only product in China to enter the NDA stage, breaking global technical monopolies [4][5] - The plan links the wealth incentives of the domestic entrepreneurial team to the market performance of these scarce assets, enhancing their strategic focus in overcoming challenges in the industrialization of protein drugs [5] - Overall, the full circulation enables Baoyi Pharmaceutical to transition from a technology-focused biotech to a mature biopharma, providing flexibility for future mergers or technology licensing through optimized capital structure [5]

Group 1 - The core viewpoint of the article highlights that Shanxi Installation (02520) has transferred shares from China Merchants Securities to GF Securities in Hong Kong, with a market value of HKD 255 million, accounting for 29.05% of the total [1] - On December 1, 2025, Shanxi Installation's application for the overseas listing of its unlisted H-shares was accepted by the China Securities Regulatory Commission, making it the first company in Shanxi Province to pursue full circulation of H-shares [1] - Following the completion of the share conversion, the circulating shares of Shanxi Installation will increase from 373 million to 1.373 billion, significantly enhancing the company's circulating capital and market value, which is expected to attract more capital attention [1] Group 2 - On December 23, Zhuoran Co., Ltd. announced that its wholly-owned subsidiary Zhuoran Smart signed a supplementary agreement for the EPC contract of the Inner Mongolia Dongjing Zhongke New Materials Co., Ltd. project, which involves an annual production of 1.2 million tons of PBAT biodegradable polyester [1] - The total investment for the Inner Mongolia PBAT project is set at RMB 5.5 billion, and upon completion, it will become the largest single PBAT biodegradable polyester production line in China [1] - Shanxi Installation is the EPC contractor for this project, marking its first contract in the PBAT biodegradable polyester sector [1]

Group 1 - The core point of the article highlights that Shanxi Installation (02520) has transferred shares from China Merchants Securities to GF Securities Hong Kong, with a market value of HKD 255 million, accounting for 29.05% of the total [1] - On December 1, 2025, Shanxi Installation's application for the overseas listing of its unlisted H-shares was accepted by the China Securities Regulatory Commission, making it the first company in Shanxi Province to pursue full circulation of H-shares [1] - Following the conversion, the circulating shares of Shanxi Installation will increase from 373 million to 1.373 billion, significantly enhancing the company's circulating capital and market value, which is expected to attract more capital attention [1] Group 2 - On December 23, Zhuoran Co., Ltd. announced that its wholly-owned subsidiary Zhuoran Smart signed a supplementary agreement for the EPC contract of the Inner Mongolia PBAT biodegradable polyester project with Shanxi Installation and two other companies [1] - The total investment for the Inner Mongolia PBAT project is set at RMB 5.5 billion, and once completed, it will become the largest single PBAT biodegradable polyester production line in China [1] - Shanxi Installation is the EPC contractor for this project, marking its first contract in the PBAT biodegradable polyester sector [1]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或 完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等 內容而引致的任何損失承擔任何責任。 HEBEI LIANJI TECHNOLOGY INDUSTRIAL DEVELOPMENT CO., LTD. 河 北 聯 集 科 技 產 業 發 展 股 份 有 限 公 司 （「本公司」） （ 於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」） 的要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即 代表 閣下知悉、接納並向本公司、其保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據向香港公司註冊處處長註 冊的本公司招股章程作出投資決定；招股章程的文本將於發售期內向公眾人士刊發。 (a) 本 文 件 僅 為 向 香 港 公 眾 人 士 提 供 有 關 本 公 ...

Group 1 - Baima Tea Industry, known as the first high-end Chinese tea stock, was listed on the Hong Kong Stock Exchange on October 28, 2025, with an initial stock price surge of 86.7%, reaching a market value close to HK$ 8 billion [1][3] - However, the stock price quickly fell, losing 70% of its market value within two months, highlighting the market's skepticism towards the high-end Chinese tea business model represented by Baima Tea [1][3] - The company has faced challenges in its performance, with revenue growth slowing down significantly from 16.72% in 2023 to just 0.99% in 2024, and a decline in revenue of 4.42% in the first half of 2025 [7][8] Group 2 - Baima Tea has experienced a significant loss of franchisees, with over 300 franchisees leaving since 2022, which poses a substantial threat to its business model that heavily relies on franchising [10] - The changing consumer preferences have shifted from high-end gifting to a focus on the taste and experience of tea, which Baima Tea has struggled to adapt to despite attempts to launch a younger sub-brand [11][14] - The overall tea industry is facing structural challenges, including a slowdown in market growth and intense competition, with Baima Tea holding only a 1.7% market share in the high-end segment despite being the largest player [16][17] Group 3 - The company has announced a plan for full circulation of H-shares, which could increase the market's liquidity by 60%, but this move may also raise concerns about potential selling pressure from investors [6] - The tea industry is experiencing a transformation, with a need to leverage regional characteristics and enhance product quality to meet market demands [18][19] - Future trends indicate a growing demand for health-oriented and customized tea products, as well as an emphasis on enhancing consumer experience through improved service and cross-industry collaborations [20][21][24]

赛目科技(02571)公布，董事会于2025年12月30日审议及批准公司若干股东所持公司65,081,360股境内非 上市股份(佔截至本公告日期公司已发行股本总额的约48.81%)转换为公司H股(H股全流通)。于取得所有 相关批准(包括中国证监会的备案通知)及遵守所有适用法律、规则及法规后，该等境内非上市股份将转 换为公司H股，而公司将向联交所申请批准该等H股于联交所主板上市及买卖。 根据本公司的公司章程，H股全流通及转换并上市毋须召开股东大会作批准。截至本公告日期，公司尚 未向中国证监会提交H股全流通备案申请，转换及上市的实施计划详情尚未落实。 ...

Core Viewpoint - The company Haiwei Co., Ltd. (09609) has announced the approval of a proposal for full circulation of H-shares, allowing the conversion of 92.2181 million unlisted shares held by five shareholders into H-shares, which represents approximately 57.94% of the total issued shares as of the announcement date [1] Group 1 - The board of directors has reviewed and approved the implementation of full circulation for H-shares [1] - The conversion involves 92.2181 million shares, which is a significant portion of the company's total issued shares [1] - Following the completion of the over-allotment option mentioned in the announcement dated December 28, 2025, the converted shares will represent about 57.30% of the total issued shares [1]

Core Viewpoint - Haiwei Co., Ltd. has announced the approval of a proposal for full circulation of H-shares, allowing the conversion of 92.2181 million unlisted shares held by five shareholders into H-shares, representing approximately 57.94% of the total issued shares as of the announcement date [1] Group 1 - The company’s board has reviewed and approved the implementation of full circulation for H-shares [1] - The conversion involves 92.2181 million shares, which is a significant portion of the company's total issued shares [1] - Following the completion of the over-allotment option mentioned in the announcement dated December 28, 2025, the converted shares will represent approximately 57.30% of the total issued shares [1]